secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001140361-23-034123
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q4 net sales up 4.7% to $91.1M; GAAP loss $0.54/share
-------------------------------------------------------------------

- Med Tech segment grew 17.2% to $26.5M, driven by Auryon +22%, NanoKnife +28%, AlphaVac +87%.
- GAAP net loss $21.5M ($0.54/share) includes $14.5M goodwill impairment from divestiture of Dialysis/BioSentry to Merit Medical for $100M cash.
- FY2024 guidance: net sales $328-333M; gross margin 50-52%; adjusted loss per share $0.28-$0.34.
- Pro forma revenue for FY23 (ex-divested businesses) was $306.3M; adjusted loss $0.43/share.
- Subsequent to quarter end, used divestiture proceeds to extinguish $50M debt; cash $44.6M at May 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/0001140361-23-034123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/brhc20055777_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-034123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer